| Identification | Back Directory | [Name]
L-Alanine, N-[2,6-dichloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-[(3,5-dihydroxybenzoyl)amino]- | [CAS]
264275-77-6 | [Synonyms]
XVA143
L-Alanine, N-[2,6-dichloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-[(3,5-dihydroxybenzoyl)amino]- | [Molecular Formula]
C25H21Cl2N3O8 | [MOL File]
264275-77-6.mol | [Molecular Weight]
562.36 |
| Hazard Information | Back Directory | [Description]
XVA143 is a α/β I allosteric inhibitor of the integrin leucocyte function-associated antigen-1 (αLβ2, LFA-1) which plays crucial roles in T cell adhesion, migration and immunological synapse (IS) formation. Consequently, αLβ2 is an important therapeutic target in autoimmunity. | [Uses]
XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo[1]. | [References]
[1] Azucena Salas, et al. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity. 2004 Apr;20(4):393-406. DOI:10.1016/s1074-7613(04)00082-2
[2] Mélanie R Tardif, et al. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob Agents Chemother. 2009 Nov;53(11):4656-66. DOI:10.1128/AAC.00117-09 |
|
|